Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8337020 | 0.83 | CA2 (0.60) | LMNACA2ALDH1A1SMN1; SMN2HTT | |
| SCHEMBL1146125 | 0.81 | PSIP1 (0.59) | LMNACA2ALDH1A1SMN1; SMN2HTT | |
| SCHEMBL2248882 | 0.81 | CA1 (0.55) | LMNACA2ALDH1A1SMN1; SMN2HTT | |
| SCHEMBL15699683 | 0.81 | ALDH1A1 (0.53) | LMNAALDH1A1SMN1; SMN2HTTHTR2A | |
| SCHEMBL3407737 | 0.81 | ALDH1A1 (0.53) | LMNACA2ALDH1A1SMN1; SMN2HTT | |
| SCHEMBL28681551 | 0.81 | CA2 (0.55) | LMNACA2ALDH1A1SMN1; SMN2HTT | |
| SCHEMBL3069358 | 0.81 | LMNA (0.53) | LMNAALDH1A1SMN1; SMN2HTTTSHR | |
| SCHEMBL5024746 | 0.81 | LMNA (0.70) | LMNACA2ALDH1A1SMN1; SMN2HTT | |
| SCHEMBL3056367 | 0.81 | ALDH1A1 (0.53) | LMNAALDH1A1SMN1; SMN2HTTTSHR | |
| SCHEMBL12824942 | 0.80 | CA2 (0.50) | LMNACA2ALDH1A1SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213108-A1 | DEAZAGUAINE COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION | 2022-07-07 | — | — | US | disclosed |
| US-10287225-B2 | Chain multiyne compound, preparation method and application thereof | XIAMEN UNIVERSITY (CN) | 2019-05-14 | — | — | US | disclosed |
| US-20180065908-A1 | CHAIN MULTIYNE COMPOUND, PREPARATION METHOD AND APPLICATION THEREOF | XIAMEN UNIVERSITY (CN) | 2018-03-08 | — | — | US | disclosed |
| US-20180065908-A1 | CHAIN MULTIYNE COMPOUND, PREPARATION METHOD AND APPLICATION THEREOF | XIAMEN UNIVERSITY (CN) | 2018-03-08 | — | — | US | disclosed |
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-03-08 | — | — | US | disclosed |
| US-9751890-B2 | Heteroaryl derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-09-05 | — | — | US | disclosed |
| WO-2017112777-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2017-06-29 | — | — | WO | disclosed |
| US-20170107225-A1 | HETEROARYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED | 2017-04-20 | — | — | US | disclosed |
| EP-2086963-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-2815750-A1 | 5-cyano-4-(pyrrolo [2,3b] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2014-12-24 | — | — | EP | disclosed |
| US-20120329785-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120329780-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120322798-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120309794-A1 | COMPOUNDS INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH) AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | UNIVERSITÀ DI PISA (IT) | 2012-12-06 | — | — | US | disclosed |
| US-8198273-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2010-11-11 | — | — | US | disclosed |
| US-7659268-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-02-09 | — | — | US | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107225-A1 | HETEROARYL DERIVATIVES AS CFTR MODULATORS | CFTR, ABCB1, ABCD3 | LMNA 4037/4885CA2 3942/4885ALDH1A1 2397/4885 |
| US-20220213108-A1 | DEAZAGUAINE COMPOUNDS AS JAK2 V617F INHIBITORS | JAK2, JAK1, VHL | LMNA 4343/4885CA2 1908/4885ALDH1A1 1812/4885 |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | CFTR, ABCC8, ABCB1 | LMNA 2779/4885CA2 3603/4885ALDH1A1 3710/4885 |
| US-20120322798-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | LMNA 3485/4885CA2 2614/4885ALDH1A1 1991/4885 |
| US-20120309794-A1 | COMPOUNDS INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH) AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | LDHA, LDHB, DLD | LMNA 755/4885CA2 74/4885ALDH1A1 84/4885 |
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | CCNO, PTGDR, CCNE1 | LMNA 2404/4885CA2 2606/4885ALDH1A1 2970/4885 |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | LMNA 3170/4885CA2 2566/4885ALDH1A1 2193/4885 |
| US-20120329780-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK | LMNA 3015/4885CA2 3513/4885ALDH1A1 4333/4885 |
| US-20120329785-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK3 | LMNA 3020/4885CA2 4069/4885ALDH1A1 4394/4885 |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | BRAF, ARAF, RAF1 | LMNA 3118/4885CA2 2113/4885ALDH1A1 999/4885 |
| US-20180065908-A1 | CHAIN MULTIYNE COMPOUND, PREPARATION METHOD AND APPLICATION THEREOF | SQLE, COASY, MCCC2 | LMNA 1741/4885CA2 3640/4885ALDH1A1 761/4885 |
| US-10287225-B2 | Chain multiyne compound, preparation method and application thereof | SQLE, COASY, MCCC2 | LMNA 1741/4885CA2 3640/4885ALDH1A1 761/4885 |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | LMNA 2451/4885CA2 3424/4885ALDH1A1 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.